Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SCYX.US
id: 867
Scynexis (SCYX) Allergic Medicines Case
D. New Jersey
Court2:23-cv-22082
Case number03/31/2023
Class period Start09/22/2023
Class period End01/06/2024
Lead Plaintiff motion deadline- Scynexis recalled its medicines due to potential allergic reactions.
- On September 26, 2023, the truth came out, leading to a 11% $SCYX fall.
On September 25, 2023, Scynexis recalled its antifungal medication ibrexafungerp and temporarily halted clinical trials due to contamination risk.
This was caused by an unwanted substance found during production that could lead to allergic reactions and hypersensitivity.
This news caused $SCYX fall by 11% and $9.29M loss of market cap, damaging shareholders.
Given all this information, investors have reason to suspect that Scynexis misled about the effectiveness and safety of its drug.
Case Status
Motion to dismiss
Alleged Offence
Mismanagement,
Misleading Statements,
Negligence,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
09/26/2023
Filing date
11/07/2023
Lead Plaintiff Deadline
01/06/2024